Sanofi

Merck KGaA, Darmstadt, Germany has entered a strategic collaboration with Skyhawk Therapeutics valued at over $2 billion to discover novel RNA-targeting small molecules for neurological disorders with high unmet medical need.

PolyPid Ltd. has appointed Dr. Nurit Tweezer-Zaks as Chief Medical Officer, effective August 18, 2025, following positive Phase 3 SHIELD II trial results for their lead product candidate D-PLEX100.

Former Calidi Biotherapeutics Chairman and CEO Allan Camaisa has joined Res Nova Biologics' Advisory Board to accelerate development of breast cancer immunotherapies.

Sanofi has acquired rights to develop and commercialize plozasiran, a first-in-class RNAi therapeutic for familial chylomicronemia syndrome and severe hypertriglyceridemia, in Greater China for $130 million upfront plus up to $265 million in milestones.

The FDA has granted orphan drug designation to SAR446523, Sanofi's investigational GPRC5D-targeting monoclonal antibody for treating relapsed or refractory multiple myeloma.

Kling Bio has entered into a collaboration and license option agreement with Sanofi to discover neutralizing antibodies against a clinically relevant human viral pathogen using its Kling-Select platform.

Sanofi announced plans to acquire London-based biotechnology company Vicebio for $1.15 billion in cash, with potential milestone payments up to $450 million based on development achievements.

Omega Funds successfully closed its eighth fund with $647 million in capital commitments, exceeding its $600 million target despite challenging fundraising conditions.

Trogenix has appointed Atif Abbas, MD as Chief Medical Officer, bringing over 25 years of oncology drug development experience including successful IND submissions for immunotherapy compounds and regulatory approvals.

Thermo Fisher Scientific will acquire Sanofi's sterile manufacturing facility in Ridgefield, New Jersey, expanding their strategic partnership to enhance U.S. drug product manufacturing capacity.